Current Price
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. The company is headquartered in Lyon, France.
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
Earnings estimates are not available for this company.
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | MMarker The... | MRKR | $14.51M | — | 1.24 | -245.50% | -267.90% | -76.90% | -51.00% |
| 2. | BBoundless... | BOLD | $59.03M | — | 0.96 | — | — | -64.60% | — |
| 3. | MMetagenomi... | MGX | $26.15M | — | 0.28 | — | -1,411.00% | -69.40% | -74.80% |
| 4. | PPolyrizon... | PLRZ | $26.84M | — | 1.10 | — | — | -21.40% | — |
| 5. | AAardvark T... | AARD | $29.12M | — | 0.39 | — | — | -66.00% | — |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Mar 22 | Jun 22 | Sep 22 | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS | 2.88 | 4.29 | 0 | 1.67 | 0 | 0 | 0 | 0.47 |
Gross Profit | 0 | 0 | 0 | -1.67 | 0 | 0 | 0 | -0.47 |
Gross Profit % | - | - | - | - | - | - | - | - |
| 12.52 | 11.74 | 5.57 | -2.68 | 0 | 0 | 5.76 | 11.84 | |
EBIT | -12.52 | 12.61 | -5.57 | 2.68 | 0 | 0 | -5.75 | -12.31 |
OPM % | - | - | - | - | - | - | - | - |
Non-Operating Income | 0 | 2.02 | 0.53 | -0.06 | 0 | 0 | 0.06 | 0 |
PBT | -11.91 | 14.62 | -5.04 | 2.62 | 0 | 0 | -5.69 | -12.08 |
Income Tax | 0.2 | 3.74 | 0.1 | -3.32 | -0.1 | -0.1 | 0 | -0.8 |
Tax Rate % | -1.68% | 25.55% | -2.03% | -126.83% | - | - | -0.02% | 6.58% |
Net Income | -11.91 | 10.89 | -5.14 | 5.93 | 0 | 0 | -5.69 | -11.29 |
NPM % | - | - | - | - | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.37 | 10.78 | 19.72 | 3.36 | 0 | 5.28 | 0 | 0 | 0 | 0 |
COGS | 4.37 | 10.78 | 19.72 | 0.53 | 0.8 | 4.22 | 4.99 | 5.38 | 2.91 | 1.61 |
Gross Profit | 0 | 0 | 0 | -25.46 | -33.47 | 1.07 | -4.99 | -5.38 | -2.91 | -1.61 |
Gross Profit % | - | - | - | -756.93% | - | 20.2% | - | - | - | - |
| 4.58 | 18.14 | 25.78 | 34.25 | 48.07 | 69.36 | 68.83 | 56.52 | 27.15 | 23.81 | |
EBIT | -8.95 | -18.43 | -26.21 | -30.89 | -43.62 | 5.28 | -72.55 | -56.52 | -32.08 | -25.42 |
OPM % | -204.81% | -171.04% | -132.92% | -918.22% | - | 100% | - | - | - | - |
Non-Operating Income | -1.46 | 1.2 | 4.31 | -2.64 | 0 | -67.94 | -0.75 | 2.72 | 32.38 | 0 |
PBT | -10.4 | -17.23 | -21.9 | -33.53 | -38.22 | -62.66 | -73.3 | -53.8 | 0.29 | -24.73 |
Income Tax | -1.54 | -2.22 | 0.01 | -0 | 0 | -0 | 0 | 0 | 0.52 | -1.25 |
Tax Rate % | 14.84% | 12.89% | -0.05% | 0.01% | -0.01% | 0% | 0% | 0% | 177.82% | 5.04% |
Net Income | -8.86 | -15.01 | -21.91 | -33.53 | -38.22 | -62.66 | -73.3 | -53.8 | -0.23 | -23.49 |
NPM % | -202.79% | -139.32% | -111.13% | -996.73% | - | -1186.05% | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| 36.99 | 45.63 | 37.65 | 185.53 | 134.37 | 73.17 | 44.45 | 33.7 | 38.79 | 10.47 | |
| 0 | 0 | 0 | 0 | 0 | 0.03 | 0.03 | 0.48 | 0.04 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 35.64 | 29.09 | 25.83 | 0 | 0 | |
| 2.54 | 6.52 | 4.89 | 6.04 | 15.54 | 8.4 | 5.18 | 6.34 | 3.8 | 5.75 | |
| 1.08 | 0.85 | 2.43 | 3.69 | 17.93 | 1.3 | 1.66 | 0.42 | 3.18 | 35.09 | |
Total Assets | 40.61 | 53 | 44.97 | 195.26 | 167.84 | 118.55 | 80.4 | 66.77 | 45.81 | 51.31 |
| 0.69 | 0.79 | 0.87 | 1.79 | 1.79 | 1.79 | 2.01 | 3.1 | 3.1 | 6.08 | |
| 35.14 | 46.34 | 34.77 | 179.63 | 143.81 | 83.77 | 24.53 | 19.74 | 20.38 | 19.54 | |
| 0.77 | 0.71 | 2.87 | 2.85 | 2.02 | 14.12 | 27.45 | 25.38 | 13.57 | 10.92 | |
| 2.59 | 3.82 | 6.3 | 8.9 | 16.71 | 14.67 | 21.18 | 14.21 | 8.29 | 11.38 | |
| 1.43 | 1.34 | 0.17 | 2.1 | 3.51 | 4.2 | 5.24 | 4.33 | 0.47 | 3.4 | |
Total Liabilities | 40.61 | 53 | 44.97 | 195.26 | 167.84 | 118.55 | 80.4 | 66.77 | 45.81 | 51.31 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.24 | -14.58 | -17.61 | -24.7 | -39.27 | -43.31 | -51.72 | -56.77 | -31.76 | -24.37 | |
| -0.42 | -0.28 | -1.79 | -1.79 | -15.04 | -19.84 | -1.48 | -0.34 | 38.13 | 0.17 | |
| 29.53 | 23.52 | 11.39 | 177.54 | -0.82 | 0.04 | 25.45 | 44.71 | -1.77 | -3.78 | |
Net CFNet Cash Flow | 21.88 | 8.66 | -8.01 | 151.05 | -55.13 | -63.11 | -27.75 | -12.4 | 4.59 | -27.97 |
FCFFree Cash Flow | -7.66 | -14.85 | -19.36 | -26.39 | -53.49 | -63.44 | -52.86 | -57.07 | -31.85 | -24.58 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| -35.9% | -36.2% | -52.9% | -30.9% | -23.4% | -54.2% | -130.8% | -217.9% | -1.0% | -95.7% | |
| 0.02 | 0.02 | 0.08 | 0.02 | 0.01 | 0.17 | 1.03 | 1.11 | 0.58 | 0.43 | |
| 9.28 | 9.24 | 6.70 | 16.51 | 7.26 | 4.10 | 1.69 | 2.00 | 3.65 | 1.06 | |
| 0.15 | 0.23 | 0.40 | 0.03 | - | 0.04 | 0.00 | 0.00 | 0.00 | - | |
Cash Conversion | 0.82 | 0.97 | 0.80 | 0.74 | 1.03 | 0.69 | 0.71 | 1.06 | 139.93 | 1.04 |
Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| 142.5% | 146.6% | 83.0% | -82.9% | - | - | -100.0% | - | - | - | |
| - | - | - | - | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | - | |
| 5.00 | 3.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 | 2.00 | 4.00 | 1.00 | |
| -1.78 | -1.14 | -2.31 | 1.13 | - | - | - | - | - | - | |
| 50.00 | 50.00 | 50.00 | 33.33 | 50.00 | 46.67 | 20.00 | 20.00 | 30.00 | 40.00 | |
| -2.0% | -1.4% | -1.1% | -10.0% | - | -11.9% | - | - | - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns PHAXIAM Therapeutics SA ADR, from SEC filings
Shares sold short · updated twice a month
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 29 Feb 2024 | 1,146 | -51.2% | 1.00 | |
| 15 Feb 2024 | 2,347 | -68.6% | 3.28 | |
| 31 Jan 2024 | 7,475 | +55.5% | 2.53 | |
| 12 Jan 2024 | 4,808 | -27.1% | 4.28 | |
| 29 Dec 2023 | 6,594 | +9.9% | 3.56 | |
| 15 Dec 2023 | 5,998 | -50.7% | 1.90 | |
| 30 Nov 2023 | 12,161 | -10.3% | 2.19 | |
| 15 Nov 2023 | 13,564 | -10.8% | 22.38 | |
| 31 Oct 2023 | 15,199 | -17.1% | 5.49 | |
| 13 Oct 2023 | 18,327 | -24.0% | 4.94 | |
| 29 Sep 2023 | 24,118 | -87.9% | 1.00 | |
| 15 Sep 2023 | 199,964 | -3.9% | 15.58 | |
| 31 Aug 2023 | 208,025 | -46.5% | 12.94 | |
| 15 Aug 2023 | 388,933 | +2085.3% | 1.00 | |
| 31 Jul 2023 | 17,798 | -7.0% | 3.30 | |
| 14 Jul 2023 | 19,146 | -28.9% | 3.21 | |
| 30 Jun 2023 | 26,924 | +51.3% | 2.87 |
FINRA consolidated short interest, reported twice a month for every US listing.
PHAXIAM Therapeutics SA ADR's SEC filings and earnings call transcripts
What recent news says about PHAXIAM Therapeutics SA ADR, scored for sentiment.